PMID- 11426550
OWN - NLM
STAT- MEDLINE
DCOM- 20020221
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 40
IP  - 3-4
DP  - 2001 Jan
TI  - The combination of zidovudine and interferon alpha-2B in the treatment of adult 
      T-cell leukemia/lymphoma.
PG  - 287-94
AB  - Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy 
      with a poor survival despite aggressive multiagent chemotherapy. The combination 
      of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has 
      been reported to induce remissions in patients with ATL. The purpose of this 
      study was to evaluate the clinical response and toxicity following administration 
      of a combination of IFNalpha-2b and AZT in patients with human T-cell 
      lymphotropic virus type I (HTLV-I)-associated ATL. Eighteen patients with ATL 
      (chronic. crisis, acute or lymphoma type) were treated with the combination of 
      AZT (50 - 200 mg orally 5 times a day) and IFNalpha-2b (2.5 - 10 million units 
      subcutaneously daily). Three patients had objective responses lasting more than 
      one month. One patient had a clinical complete remission, lasting 21.6 months and 
      two patients had partial remissions lasting 3.7 and 26.5 months. Six patients 
      were not considered evaluable for response due to short and/or interrupted 
      periods of treatment. Seventeen patients have died with a median survival time 
      after initiation of therapy of 6 months. Neutropenia and thrombocytopenia were 
      the dose limiting toxicities. In conclusion, the response rate in this study was 
      lower than noted in the two previous published series. This may be due to the 
      amount and type of prior treatment our patients had received.
FAU - White, J D
AU  - White JD
AD  - Metabolism Branch, National Cancer Institute, University of the West Indies, 
      Kingston, Jamaica.
FAU - Wharfe, G
AU  - Wharfe G
FAU - Stewart, D M
AU  - Stewart DM
FAU - Maher, V E
AU  - Maher VE
FAU - Eicher, D
AU  - Eicher D
FAU - Herring, B
AU  - Herring B
FAU - Derby, M
AU  - Derby M
FAU - Jackson-Booth, P G
AU  - Jackson-Booth PG
FAU - Marshall, M
AU  - Marshall M
FAU - Lucy, D
AU  - Lucy D
FAU - Jain, A
AU  - Jain A
FAU - Cranston, B
AU  - Cranston B
FAU - Hanchard, B
AU  - Hanchard B
FAU - Lee, C C
AU  - Lee CC
FAU - Top, L E
AU  - Top LE
FAU - Fleisher, T A
AU  - Fleisher TA
FAU - Nelson, D L
AU  - Nelson DL
FAU - Waldmann, T A
AU  - Waldmann TA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 4B9XT59T7S (Zidovudine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/toxicity
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage/toxicity
MH  - Leukemia-Lymphoma, Adult T-Cell/complications/*drug therapy/mortality
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Neutropenia/chemically induced
MH  - Recombinant Proteins
MH  - Remission Induction
MH  - Skin Tests
MH  - Thrombocytopenia/chemically induced
MH  - Treatment Outcome
MH  - Zidovudine/*administration & dosage/toxicity
EDAT- 2001/06/28 10:00
MHDA- 2002/02/22 10:01
CRDT- 2001/06/28 10:00
PHST- 2001/06/28 10:00 [pubmed]
PHST- 2002/02/22 10:01 [medline]
PHST- 2001/06/28 10:00 [entrez]
AID - 10.3109/10428190109057927 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2001 Jan;40(3-4):287-94. doi: 10.3109/10428190109057927.